Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))

on behalf of the RELIVE Investigators

Research output: Contribution to journalComment/debatepeer-review


Merle P, Blanc J-F, Phelip J-M, et al, on behalf of the RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4: 454–65—The appendix for this Article has been updated. This correction has been made to the online version as of June 3, 2019.

Original languageEnglish (US)
Pages (from-to)e6
JournalThe Lancet Gastroenterology and Hepatology
Issue number7
StatePublished - Jul 1 2019

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))'. Together they form a unique fingerprint.

Cite this